Skip to main content
Caplight Logo









CROSSPOINT Therapeutics

CROSSPOINT Therapeutics

Private
South KoreaHealthcare & Life Scienceshttps://www.crosspointrx.com/

Last Round

VC Round

Mar 4, 2026

Total Funding Raised

$2.82M

Momentum

Top 50%

of companies Caplight tracks

Company Overview

CROSSPOINT Therapeutics is a biotechnology company that develops next-generation antibody therapies using its proprietary Stealth-Body platform to reduce toxicity and side effects.

Sector

Healthcare & Life Sciences

Verticals

Biotechnology, Drug Discovery, Precision Medicine

Business Model

B2B

Customer Profile

Services & Consulting, Data as a Service

AI Layer

Non-AI

Keywords

antibody engineeringantibody-drug conjugatesADCimmunotherapyFc-silencingnext-gen biologicsoncology therapeuticsbiotech platformdrug delivery platformtherapeutic indexpreclinical drug developmentbiotech licensingprotein deliverygene deliverydrug discovery

Historical Pricing

Historical view of private secondary pricing and transaction trends.

Unlock Pricing Charts

Sign up to view complete historical pricing and secondary transactions.

Caplight Momentum Score

Proprietary index based on bid/ask volume and sentiment.

View Momentum History

Track how buyer interest and sentiment changes over time.

CROSSPOINT Therapeutics Comparables

Compare CROSSPOINT Therapeutics with similar companies based on industry and business-model similarity.

CROSSPOINT Therapeutics comparables — related companies by embedding similarity
CompanySimilarityMarket Cap
mAbsolve Ltd.
91%
Proteinea
78%
Xencor, Inc.
69%

CROSSPOINT Therapeutics Funding Rounds

Historical fundraising activity

Data table
RoundDateAmount RaisedValuationInvestorsSources
VC RoundMar 4, 2026
GrantAug 8, 2024
SeedApr 1, 2024

Key People

Founding team and executive leadership

Ki Hwan C.

Chief Technology Officer

Executive Team

CROSSPOINT Therapeutics Investors

Notable investors and investment history

Market signals

Structured signals derived from secondary market and firmographic data.

  • Mar 4, 2026

    $2.38M round led by SU Investment Capital and Kudos Ventures.

CROSSPOINT Therapeutics Filings

Explore SEC and related filing metadata, where available.

CROSSPOINT Therapeutics filings preview — column headings only; records require access
TypeDateAmount OfferedAmount SoldFilingPagesDownload

Filing documents are not displayed on this public page. Request access to learn about available coverage.

Request access

Frequently Asked Questions

Common questions about CROSSPOINT Therapeutics's valuation, stock price, and market status.

Is CROSSPOINT Therapeutics a public or private company?

CROSSPOINT Therapeutics is a private company.

What is the current stock price of CROSSPOINT Therapeutics?

CROSSPOINT Therapeutics is a private company with no public stock price. No recent secondary market data is available.

How much is CROSSPOINT Therapeutics worth (valuation)?

Valuation information for CROSSPOINT Therapeutics is not publicly available.

Can I buy CROSSPOINT Therapeutics stock?

CROSSPOINT Therapeutics shares may be available on secondary markets subject to transfer restrictions. Caplight facilitates secondary market transactions for accredited investors. Visit https://www.caplight.com to learn more.

When was CROSSPOINT Therapeutics's last funding round?

CROSSPOINT Therapeutics's most recent funding round was VC Round on March 27, 2026.

Who are the main investors in CROSSPOINT Therapeutics?

Key investors in CROSSPOINT Therapeutics include Kudos Ventures.

Will CROSSPOINT Therapeutics IPO soon?

No public IPO plans have been announced for CROSSPOINT Therapeutics.

How can I track CROSSPOINT Therapeutics secondary market activity?

Caplight tracks bids, offers, and trades for private companies. Visit https://www.caplight.com to monitor CROSSPOINT Therapeutics's secondary market activity and sign up for updates.

Firmographic Details

HeadquartersSouth Korea
Employee Range2
Year Founded2022
Last FundingMar 4, 2026

Institutional Data Access

Join leading institutional investors using Caplight to access private market data, discover pricing, and execute secondary block trades.

Requires verified institutional or accredited status.

See something wrong or outdated?